Replies to post #14057 on CytoSorbents Corporation (CTSO)

[berthabluefish1]

About 31:27 into the presentation yesterday From Kathleen Bloch.She was asked about other ICU Indications for FDA.She said they would go after more Narrowly Focused Indications.Should hear something by the first half 2019.I wonder if she means for CRS and Cart T cell therapy.

[berthabluefish1]

Kathleen also said HemoDefend will be our first FDA approved product.

[Good Sport]

Allopathic suppression care with no "cure" of any disease is the leading killer of people in this nation and will remain so as long as AMA and Big Pharma (toxic med makers) own the FDA. $7 bucks by year end is my guess. Let's hope Chan doesn't make some give the farm away deal to a big pharma player (that hurts ctso shareholders) while he walks out the back door. I've seen that happen in other small biotechnology companies. I hope the cytosorbents board stays on top of this mgmt.